1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Staphylococcal Infections - Pipeline Review, H2 2013

Staphylococcal Infections - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 64 pages

Staphylococcal Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Staphylococcal Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcal Infections. Staphylococcal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Staphylococcal Infections.
- A review of the Staphylococcal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Staphylococcal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Staphylococcal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Staphylococcal Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Staphylococcal Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Staphylococcal Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Staphylococcal Infections 8
Staphylococcal Infections Therapeutics under Development by Companies 10
Staphylococcal Infections Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Staphylococcal Infections Therapeutics - Products under Development by Companies 15
Staphylococcal Infections Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Staphylococcal Infections Therapeutics Development 17
Affinium Pharmaceuticals, Inc. 17
Nymox Pharmaceutical Corporation 18
Evolva SA 19
Destiny Pharma Ltd. 20
Viral Genetics, Inc. 21
Sequoia Sciences, Inc. 22
TAXIS Pharmaceuticals, Inc. 23
Staphylococcal Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AFN-1252 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
AFN-1252 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
NXT-1021 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
XF-73 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
CDI-936 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CF-301 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
VGV-S - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
EV-035 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
TX-436 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Compound 4b-4h - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
CDI-538 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Antibacterial Program - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Compound-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Monoclonal Antibody Against Staphylococcal Enterotoxin B - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Compound-A - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Compound-B - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Staphylococcal Infections Therapeutics - Drug Profile Updates 49
Staphylococcal Infections Therapeutics - Dormant Products 54
Staphylococcal Infections - Product Development Milestones 55
Featured News and Press Releases 55
Sep 30, 2013: Protalex Announces Two Posters Accepted for Presentation at 2013 American College of Rheumatology Annual Meeting 55
May 20, 2013: Destiny Pharma Announces Enrollment In Part 2 Of NIAID-funded US Clinical Trial Of Anti-staphylococcal Nasal Gel XF-73 56
Feb 26, 2013: Integrated BioTherapeutics Initiates Phase I Study Of Staphylococcal Enterotoxin B Vaccine, STEBVAX 56
Dec 14, 2012: HIV Drug Might Defuse Deadly Staph Infections, NYU Study Finds 57
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 58
Aug 07, 2012: Affinium Pharma Completes Recruitment For Phase II Clinical Trial Of AFN-1252 In Acute Bacterial Skin and Skin Structure Infections 59
Oct 25, 2011: Fujifilm And ContraFect Announce Development And Manufacturing Collaboration For Anti-Staph Biologic 60
Sep 16, 2011: GlycoVaxyn's Staphylococcus Aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection 60
Aug 15, 2011: Destiny Pharma Announces Selection Of XF-73 For Clinical Evaluation From US National Institute of Allergy And Infectious Diseases 61
May 07, 2011: Cempra To Present Vitro Activity Data On TAKSTA 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64



List of Tables

Number of Products Under Development for Staphylococcal Infections, H2 2013 8
Products under Development for Staphylococcal Infections - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Affinium Pharmaceuticals, Inc., H2 2013 17
Nymox Pharmaceutical Corporation, H2 2013 18
Evolva SA, H2 2013 19
Destiny Pharma Ltd., H2 2013 20
Viral Genetics, Inc., H2 2013 21
Sequoia Sciences, Inc., H2 2013 22
TAXIS Pharmaceuticals, Inc., H2 2013 23
Assessment by Monotherapy Products, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 28
Staphylococcal Infections Therapeutics - Drug Profile Updates 49
Staphylococcal Infections Therapeutics - Dormant Products 54



List of Figures

Number of Products under Development for Staphylococcal Infections, H2 2013 8
Products under Development for Staphylococcal Infections - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 24
Assessment by Route of Administration, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Molecule Type, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 28



Companies Mentioned

Affinium Pharmaceuticals, Inc.
Nymox Pharmaceutical Corporation
Evolva SA
Destiny Pharma Ltd.
Viral Genetics, Inc.
Sequoia Sciences, Inc.
TAXIS Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry - Analyst Report, December 2016

  • December 2016
    15 pages
  • Hepatitis C  

  • India  

    World  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

Related Market Segments :

Infectious Disease

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.